Recanalization of chronic coronary occlusion, аntegrade approach: indications, modern amenities and own experience
S.М. Furkalo
References
1. Burzotta F., De Vita M., Lefévre T. et al. Radial approach for percutaneous coronary interventions on chronic total occlusions: technical issues and data review // Catheter Cardiovasc. Interv.– 2014.– Vol. 83 (1).– Р. 47–57.
2. Christofferson R.D., Lehmann K.G., Martin G.V. et al. Effect of chronic total coronary occlusion on treatment strategy // Am. J. Cardiol.– 2005.– Vol. 95.– Р. 1088–1091.
3. Di Mario C., Werner G.S., Sianos G. et al. European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the Euro CTO Club // EuroIntervention.– 2007.– Vol. 3.– Р. 30–43.
4. Hirokami M., Saito S., Muto H. Anchoring technique to improve guiding catheter support in coronary angioplasty of chronic total occlusions // Catheter. Cardiovasc. Interv.– 2006.– Vol. 67.– Р. 366–371.
5. Ivanhoe R.J., Weintraub W.S., Douglas J.S. et al. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long term clinical follow up // Circulation.– 1992.– Vol. 85.– Р. 106–115.
6. Kim J.Y., Yoon J.H., Jung H.S. et al. The experience of transradial coronary intervention for chronic total occlusion // Korean Circ. J.– 2003.– Vol. 33.– Р. 805–812.
7. Katsuragawa M., Fujiwara H., Miyamae M., Sasayama S. Histologic studies in percutaneous transluminal coronary angioplasty for chronic total occlusion: comparison of tapering and abrupt types of occlusion and short and long occluded segments // J. Am. Coll. Cardiol.– 1993.– Vol. 21.– Р. 604–609.
8. Matsubara T., Murata A., Kanyama H., Ogino A. IVUS-guided wiring technique: promising approach for the chronic total occlusion // Catheter. Cardiovasc. Interv.– 2004.– Vol. 61.– Р. 381–386.
9. Mitsudo K., Yamashita T., Asakura Y. et al. Recanalization strategy for chronic total occlusions with tapered and stiff-tip guidewire // J. Invasive. Cardiol.– 2008.– Vol. 20.– Р. 571–577.
10. Mollet N.R., Hoye A., Lemos P.A. et al. Value of preprocedure multislice computed tomographic coronary angiography to predict the outcome of percutaneous recanalisation of chronic total occlusions // Am. J. Cardiol.– 2005.– Vol. 95.– Р. 240–243.
11. Olivari Z., Rubartelli P., Piscione F. et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE) // J. Am. Coll. Cardiol.– 2003.– Vol. 41.– Р. 1672–1678.
12. Park C.S., Kim H.Y., Park H.J. et al. Clinical, electrocardiographic, and procedural characteristics of patients with coronary chronic total occlusions // Korean. Circ. J.– 2009.– Vol. 39.– Р. 111–115.
13. Rathore S., Katoh O., Matsuo H. et al. Retrograde percutaneous recanalization of chronic total occlusion of the coronary arteries: procedural outcomes and predictors of success in contemporary practice // Circ. Cardiovasc. Interv.– 2009.– Vol. 2.– Р. 124–132.
14. Rathore S., Hakeem A., Pauriah M. et al. A comparison of the transradial and the transfemoral approach in chronic total occlusion percutaneous coronary intervention // Catheter. Cardiovasc. Interv.– 2009.– Vol. 73.– Р. 883–887.
15. Rathore S., Terashima M., Suzuki T. Value of intravascular ultrasound in the management of coronary chronic total occlusions // Catheter. Cardiovasc. Interv.– 2009.– Vol. 74.– Р. 873–878.
16. Sirnes P.A., Myreng Y., Molstad P. et al. Improvement in left ventricular ejection fraction and wall motion after successful recanalization of chronic coronary occlusions // Eur. Heart J.–1998.– Vol. 19.– Р. 273–281.
17. Suero J.A., Marso S.P., Jones P.G. et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience // J. Am. Coll. Cardiol.– 2001.– Vol. 38.– Р. 409–414.
18. Singh M., Bell M.R., Berger P.B., Holmes D.R. Jr. Utility of bilateral coronary injections during complex coronary angioplasty // J. Invasive Cardiol.– 1999.– Vol. 11.– Р. 70–74.
19. Srivatsa S., Holmes D. Jr. The histopathology of angiographic chronic total coronary artery occlusions changes in neovascular pattern and intimal plaque composition associated with progressive occlusion duration // J. Invasive Cardiol.–1997.– Vol. 9.– Р. 294–301.
20. Saito S., Tanaka S., Hiroe Y. et al. Angioplasty for chronic total occlusion by using tapered-tip guidewires // Catheter Cardiovasc Interv.– 2003.– Vol. 59.– Р. 305–311.
21. Surmely J.F., Suzuki T. Parallel-wire techniquse // Chronic Total Occlusions / Ed. R. Waksman, S. Saito.– 1st ed.– West Sussex: Wiley-Blackwell.– 2009.– P. 83–85.
22.Werner G.S., Ferrari M., Heinke S. et al. Angiographic assessment of collateral connections in comparison with invasively determined collateral function in chronic coronary occlusions // Circulation.– 2003.– Vol. 107.– Р. 1972–1977.
23. Williams D.O., Holubkov R., Yeh W. et al. Percutaneous coronary intervention in the current era compared with 1985–1986: the National Heart, Lung, and Blood Institute Registries // Circulation.– 2000.– Vol. 102.– Р. 2945–2951.
| [PDF] | [Contents] |
Left ventricular remodeling in patients with acute myocardial infarction under conservative and interventional treatment
L.M. Babii, N.P. Stroganova, Yu.O. Khomenko
References
1. Беленков Ю.Н. Ремоделирование левого желудочка сердца: комплексный подход // Сердечная недостаточность.– 2004.– № 4. – С. 161–164.
2. Белов Ю.В., Вараксин В.А. Современное представление о постинфарктном ремоделировании левого желудочка // Рус. мед. журн. – 2002. – № 10.– С. 469–471.
3. Белов Ю.В. Постинфарктное ремоделирование левого желудочка сердца – от концепции к хирургическому лечению.– М.: Lt Novo, 2012.– 194 c.
4. Биленко М.В. Ишемическое и реперфузионное повреждение органов.– М.: Медицина, 1989.– 368 с.
5. Бокерия Л.А., Аленян Б.Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации, 2013 г. – М.: НЦССХ им. А.Н. Бакулева РАМН, 2014.– 180 с.
6. Коваль М. Феномен «no-flow» ложка дегтя в бочке меда реваскуляризации // Medicine Review.– 2008.– № 5 (65).– C. 132–136.
7. Коронарная и сердечная недостаточность / Под ред. Р.С. Карпова.– Томск: STT, 2008. – 716 c.
8. Маслов Л.Н. Новые подходы к профилактике и терапии ишемических и реперфузионных повреждений сердца при остром инфаркте миокарда // Сибирский мед. журн.– 2010.– № 2, вып. 1.– С. 17–25.
9. Марков В.А., Рябов В.В., Максимов И.В. и др. Вчера, сегодня, завтра в диагностике и лечении острого инфаркта миокарда // Сибирский мед. журн.– 2011.– № 2, вып 1.– С. 8–13.
10. Рябов В.В., Соколов А.А., Рябова Т.Р., Марков В.А. Структурно-функциональная перестройка сердца в условиях современной реперфузионной терапии инфаркта миокарда // Томск: STT, 2010.– 252 c.
11. Рябова Т.Р., Рябов В.В., Соколов А.А. и др. Роль раннего ремоделирования левого желудочка в формировании хронической сердечной недостаточности у больных острым инфарктом миокарда // Сердечная недостаточность.– 2003.– № 3.– С. 130–134.
12. Рябова Т.Р., Рябов В.В. Ремоделирование левого желудочка в ранние и поздние сроки переднего инфаркта миокарда // Патология кровообращения и кардиохирургия.– 2001.– № 4.– С. 65–69.
13. Соколов Ю.Н., Соколов М.Ю., Костенко Л.Н. и др. Инвазивная кардиология.– К.: Морион, 2002.– 359 с.
14. Тетерина Т.В., Рябов В.В., Рябова Т.Р., Марков В.А. Ремоделирование левого желудочка в отдаленный 5-летний период // Сибирский мед. журн.– 2008.– № 4, вып 2.– С. 35–42.
15. Шахова Е.Б. Динамика эхокардиографических показателей функции левого желудочка у постинфарктных больных до и после стентирования коронарных артерий // Радиод.-пресс.– 2007.– Т. 1.– № 2.– С. 13–21.
16. Bax J.J., Viser F.C., Poldesmans D. et al. Relation between preoperative viability and postoperative improvement in LV EF and heart failure symptoms // J. Nucl. Med.– 2001.– Vоl. 42.– P. 79–86.
17. Berders M., Thone F., Wjnters L. et al. Structure correlates of regional myocardial dysfunction in patients with clinical coronary artery stenosis: chronic hibernation? // Cardiovasc. Pathology.– 1999.– Vol. 237.– P. 237–245.
18. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling concepts and clinical implication: a cosensua paper from an informational form on cardiac remodeling. Behalf of an international forum on cardiac remodeling // J. Am. Coll. Cardiol.– 2000.– Vol. 35.– P. 569–582.
19. Dalman J., Boersman E., Flather M. et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass for multivessel coronary artery disease: a meta analysis with 5-year patients – data from ARTSERACH-II, and SoS trial // Circulation.– 2008.– Vol. 118.– P. 1146–1154.
20. Dhoot J., Tarig Sh., Erevude A. et al. Effects oh morbid obesity on in-hospital mortality and coronary revascularization outcomes after acute myocardial infarction in the United States ?? // Amer. J. Cardiology.– 2013.– Vol. 111.– P. 1104–1110.
21. Eagles K.A., Nallamothu B.K., Mehta R.H. et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got long way to go? // Eur. Heart J.– 2008.– Vol. 29.– P. 609–617.
22. Ferrari R., Ceconi G., Curella S. et al. Ischemic precondition, myocardial stenting and hibernation: basic aspects // Amer. Heart J.– 1999.– Vol. 138.– P. 61–68.
23. Ganame J., Messflli G., Dymarkowski S. Impact of myocardial haemorrhage on left ventricular function in patients with reperfused acute myocardial infarction // Eur. Heart J.– 2009.– Vol. 20.– P. 1244–1449.
24. Glover M.V., Adgly A.A. Acute reperfusion strategies for ST-segment elevation myocardial infarction // Eur. Heart J.– 2008.– Vol. 29.– P. 571–572.
25. Hanson J.E. Review of postinfarction treatment with verapamil. Combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction and reperfusion // Basic. Res. Cardiology.– 1993.– Vol. 88.– P. 495–512.
26. Macaya C., Seruys P.W., Ruygrok P. et al. Continued benefit of coronary stenting versus ballon angioplasty one-year clinical following of the BENESTENT-II pilot study // Circulation.– 1996.– Vol. 93.– P. 412–422.
27. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observation and clinical implication // Circulation.– 1990.– Vol. 81.– P. 1161–1172.
28. Pfeffer M.A., Pfeffer J.M. Ventricular enlargement and reduced survivals after myocardial infarction // Circulation.– 1987.– Vol. 75 (Suppl. 4).– P. IV93–IV97.
29. The Task Force on myocardial revascularization of the European Society of Association of cardio-thoracic surgery (EACTS). Quide-lines on myocardial revascularization // Eur. Heart J.– 2010.– Vol. 31.– P. 2509–2555.
30. White H.D., Norric R.M., Brown M.A. et al. Left ventricular end systolic volume as the major determinat of survival after myocardial infarction // Circulation.– 1987.– Vol. 76.– P. 44–51.
| [PDF] | [Contents] |
Diagnostic difficulties in infective endocarditis
M.T. Vatutin, Ye.V. Yeshchenko, O.I. Stolika
References
1. Ватутин Н.Т. Кардиология.– Донецк: Каштан, 2008.– 446 с.
2. Ватутин Н.Т. Неотложная кардиология.– Донецк: ФО-П, 2011. 232 с.
3. Habib G., Hoen B., Tornos P. et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC) // Eur. Heart J.– 2009.– Vol. 30.– P. 2369–2413.
4. Moreillon P., Que Y.A. Infective endocarditis // Lancet.– 2004.– Vol. 363.– P. 139–149.
| [PDF] | [Contents] |
Primary and secondary prevention of thromboembolic events in atrial fibrillation
O.I. Dyadyk, L.S. Kholopov, O.V. Shchukina, N.O. Prokopenko, O.Y. Zaitseva, K.I. Chernyaeva
References
1. Пархоменко А.Н. Риск развития тромбоэмболических осложнений у больных с мерцательной аритмией и применение антикоагулянтов и антиагрегантов для профилактики инсульта // Укр. кардіол. журн.– 2002.– Додаток 2.– С. 4–14.
2. Дзяк Г.В., Васильева Л.И., Сапожниченко Л.В. и др. Антикоагулянты непрямого действия в кардиологии: показания и противопоказания, дозирование и осложнения // Ліки України.– 2009.– № 7.– С. 115–121.
3. Alexander J.H., Becker R.C., Bhatt D.L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial // Circulation. – 2009.– Vol. 19, № 22.– P. 2877–2885.
4. Alexander J.H., Lopes R.D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome // N. Engl. J. Med.– 2011.– Vol. 365.– P. 699–708.
5. Artang R., Rome E., Nielsen J.D., Vidaillet H.J. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors [електронний ресурс] // Amer. J. Cardiol. – 2013.– Режим доступу до журн.: http:// www. pii: S0002-9149(13)01709-8.
6. Bassand J.P. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents // Europace.– 2012.– Vol. 14.– P. 312–324.
7. Beasley B.N., Unger E.F., Temple R. Anticoagulant options — why the FDA approved a higher but not a lower dose of dabigatran // N. Engl. J. Med.– 2011.– Vol. 364.– P. 1788–1790.
8. Becker R., Berkowitz S.D., Breithardt G. et al. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Amer. Heart J.– 2010.– Vol. 159.– P. 340–347.
9. Bogatkevich G.S., Ludwicka-Bradley А., Silver R. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts // J. Arthritis Rheum.– 2009.– Vol. 60.– P. 3455–3464.
10. Büller H.R., Halperin J.L., Bounameaux H. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants // J. Thromb. Haemost.– 2008.– Vol. 6.– P. 227–229.
11. Camm A.J., Lip G.Y.H., Caterina R. et al. Guidelines for the management of atrial fibrillation // Eur. Heart J.– 2012.– Vol. 33.– P. 2719–2747.
12. Cid-Conde L., Lopez-Castro J. New oral anticoagulants in atrial fibrillation // Atrial fibrillation – Mechanisms and Treatment / Ed. by Tong Liu.– InTech, 2013.– Ch.9.– P. 207–238.
13. Cohen A.T., Spiro T.E., Büller H.R. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients // New Engl. J. Med.– 2013.– Vol. 368.– P. 513–523.
14. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet.– 2006.– Vol. 367.– P. 1903–1912.
15. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 364.– P. 806–817.
16. Connolly S.J., Wallentin L., Ezekowitz M.D. et al. The long term multi-center observational study of dabigatran treatment in patients with atrial fibrillation: (RELY-ABLE) study // Circulation.– 2013.– Vol. 128.– P. 237–243.
17. Connolly S.J., Pogue J., Hart R.G. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation // N. Engl. J. Med.– 2009.– Vol. 360.– P. 2066–2078.
18. Coppens M., Eikelboom J.W., Hart R.G. et al. The score identifies those patients with atrial fibrillation CHA2DS2-VASc and CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy // Eur. Heart J.– 2013.– Vol. 34.– P. 170–176.
19. Eikelboom J.W., O'Donnell M., Yusuf S. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment // Amer. Heart J.– 2010.– Vol. 159.– P. 348–353.
20. Erdoran O. Risk assessment and therapy decision in patients at low risk for stroke: CHA2DS2-VASc vs CHADS2 // Eur. Heart J.– 2013.– Vol. 34.– P. 168–169.
21. Eriksson B.I., Borris L.C., Friedman R.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty // New Engl. J. Med.– 2008.– Vol. 358.– P. 2765–2775.
22. Eriksson B.I., Dahl O.E., Huo M.H. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial // Thromb. Haemost. – 2011.– Vol. 105, № 4.– P. 721–729.
23. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial // Lancet.– 2007.– Vol. 370.– P. 949–956.
24. Eriksson B.I., Dahl O.E., Rosencher N. et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial // J. Thromb. Haemost.– 2007.– Vol. 5.– P. 2178–2185.
25. Evidence-Based Management of Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141 (Suppl. 2).– P. e152S–e184S.
26. Ezekowitz M.D., Connolly S., Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran // Amer. Heart J.– 2009.– Vol. 157.– P. 805–810.
27. Ezekowitz M.D., Reilly P. A., Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) // Amer. J. Cardiol.– 2007.– Vol. 100.– P. 1419–1426.
28. Fanikos J.R., Atay J.K., Connors J.M. Improving anticoagulation management in patients with atrial fibrillation // Pharm. Ther.– 2013.– Vol. 38, № 3.– P. 173–177.
29. Fox K.A.A., Piccini J.P. , Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment // Eur. Heart J.– 2011.– Vol. 32.– P. 2387–2394.
30. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J.– 2010.– Vol. 31.– P. 967–975.
31. Friedman R.J. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials // Orthopedics.– 2011.– Vol. 34, № 10.– P. 795–804.
32. Fu R., Wu S., Wu P. et al. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation // Europace.– 2011.– Vol. 13.– P. 31–36.
33. Galal Azzam H.A. Thrombogenesis in atrial fibrillation // Atrial Fibrillation – Mechanisms and Treatment / Ed. by Tong Liu.– InTech, 2013.– Сh.6.– P. 127–151.
34. Gerotziafas G.T., Elalamy I., Depasse F. et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban // J. Thromb. Haemost.– 2007.– Vol. 5.– P. 886–888.
35. Ginsberg J.S., Davidson B.L., Comp P. C. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery // J. Arthroplasty. – 2009.– Vol. 24, № 1.– P. 1–9.
36. Go A.S., Fang M.C., Udaltsova N. et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study // Circulation.– 2009.– Vol. 119.– P. 1363–1369.
37. Go A.S., Hylek E.M., Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? // J. Amer. Med. Assoc.– 2003.– Vol. 290.– P. 2685–2692.
38. Goldhaber S.Z., Leizorovicz A., Kakkar A.K. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients // New Engl. J. Med.– 2011.– Vol. 365.– P. 2167–2177.
39. Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med.– 2011.– Vol. 365.– P. 981–992.
40. Guyatt G.H., Akl E.A., Crowther M. et al. Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Executive summary // Chest.– 2012.– Vol. 141 (Suppl. 2).– P. 7–47.
41. Haris M., Usman U., Notaro L.A. et al. New developments in anticoagulation for atrial fibrillation // Curr. Treatment Options Cardiovasc. Med.– 2008.– Vol. 10.– P. 388–397.
42. Hart R.G., Eikelboom J.W., Ingram A.J. et al. Anticoagulants in atrial fibrillation patients with chronic kidney disease // Nat. Rev. Nephrol.– 2012.– Vol. 8.– P. 569–578.
43. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation // Ann. Intern. Med.– 2007.– Vol. 146.– P. 857–867.
44. Healey J.S., Eikelboom J., Wallentin L. et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RELY study // J. Amer. Coll. Cardiol.– 2010.– Vol. 55 (Suppl.10).– P. 4–37.
45. Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace.– 2013.– Vol. 15.– P. 625–651.
46. Hohnloser S.H., Connolly S.J. Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope // Eur. Heart J.– 2011.– Vol. 32.– P. 2347–2349.
47. Hughes M., Lip G.Y.H. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk stratification schema and cost effectiveness data // Thrombosis and Haemostasis.– 2008.– Vol. 99.– P. 295–304.
48. Hylek E.M. Therapeutic potential of oral factor Xa inhibitors // New Engl. J. Med.– 2010.– Vol. 363.– P. 2559–2561.
49. Koti M.J., Parekh A., Connolly S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion // J. Amer. Coll. Cardiol.– 2010.– Vol. 55 (Suppl.10).– P. 4–40.
50. Kubitza D., Becka M., Mueck W. et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirin // J. Clin. Pharmacol.– 2006.– Vol. 46.– P. 981–990.
51. Lane D.A., Lip G.Y.H. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation // Circulation.– 2012.– Vol. 126.– P. 860–865.
52. Lassen M.R., Raskob G.E., Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial // Lancet.– 2010.– Vol. 375.– P. 807–815.
53. Lassen M.R., Raskob G.E., Gallus А. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement // New Engl. J. Med.– 2009.– Vol. 361.– P. 594–604.
54. Lip G.Y.H., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation // Chest.– 2010.– Vol. 137.– P. 263–272.
55. Lohrmann J., Becker R.C. New anticoagulants – the path from discovery to clinical practice // New Engl. J. Med.– 2008.– Vol. 358.– P. 2827–2829.
56. Lowe B.S., Chung M.K., Klein A.L. Antithrombotic treatment and cardioversion of patients with atrial fibrillation // Atrial Fibrillation – From Bench to Bedside / Ed. by A. Natale, J. Jalife.– Totowa, N.J.: Humana Press, 2008.– Ch.12.– P. 169–184.
57. Mant J., Hobbs F.D., Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial // Lancet.– 2007.– Vol. 370.– P. 493–503.
58. Medi C., Hankey G.J., Freedman S.B. Stroke risk and antithrombotic strategies in atrial fibrillation // Stroke. – 2010.– Vol. 41, № 11.– P. 2705–2713.
59. Mega J.L. A New era for anticoagulation in AF // New Engl. J. Med.– 2011.– Vol. 365, № 11.– P. 1052–1054.
60. Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet.– 2009.– Vol. 374.– P. 29–38.
61. Montoro-Garcia S., Marin F., Lip G.Y.H. Thrombogenesis in lone atrial fibrillation: a role for soluble P-selectin? // Europace.– 2011.– Vol. 13.– P. 3–4.
62. Oldgren J., Budaj A., Granger C.B. et al. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial // Eur. Heart J.– 2011.– Vol. 32, № 22.– P. 2781–2789.
63. Olsson S.B., Rasmussen L.H., Tveit A. et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation // Thromb. Haemost.– 2010.– Vol. 103.– P. 604–612.
64. Park J.H., Joung B., Son N.H. et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation // Europace.– 2011.– Vol. 13.– P. 1541–1549.
65. Pisters R., Lane D.A., Marin F. et al. Stroke and thromboembolism in atrial fibrillation // Circulation J.– 2012.– Vol. 76.– P. 2289–2304.
66. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey // Chest.– 2010.– Vol. 138, № 5.– P. 1093–1100.
67. Riva N., Lip G.Y.H. A new era for anticoagulation in atrial fibrillation. Which anticoagulant we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? // Pol. Arch. Med. Wewn.– 2012.– Vol. 122, № 12.– P. 45–53.
68. ROCKET AF Study Investigators. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Amer. Heart J.– 2010.– Vol. 159.– P. 340–347.
69. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism // New Engl. J. Med.– 2009.– Vol. 361.– P. 2342–2352.
70. Singer D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation // Chest.– 2008.– Vol. 133.– P. 546–592.
71. Stoddard M.F. Risk of thromboembolism in new onset or transient atrial fibrillation // Progr. Cardiovasc. Dis.– 1996.– Vol. 39.– P. 69–80.
72. Turpie A.G.G. New oral anticoagulants in atrial fibrillation // Eur. Heart J.– 2007.– Vol. 29.– P. 155–165.
73. Turpie A.G.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases // Arterioscler. Thromb. Vasc. Biol.– 2007.– Vol. 27.– P. 1238–1247.
74. VanRyn J., Stangier J., Haertter S. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity // Thromb. Haemost.– 2010.– Vol. 103.– P. 1116–1127.
75. Velu S., Lip G.Y. Recent progress in antithrombotic therapy for atrial fibrillation // J. Atheroscler. Thromb. – 2011.– Vol. 18, № 4.– P. 257–273.
76. Verheugt F.W.A. Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants // Clin. Cardiol.– 2013.– Vol. 36, № 6.– P. 312–322.
77. Waldo A.L. Anticoagulation: stroke prevention in patients with atrial fibrillation // Cardiol. Clin. – 2009.– Vol. 27, № 1.– P. 125–135.
78. Weijs B., Blaauw Y., Roger J. et al. Patient using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients // Eur. Heart J.– 2011.– Vol. 32.– P. 2555–2562.
79. You J.J., Singer D.E., Howard P. A. et al. Antithrombotic therapy for atrial fibrillation antithrombotic therapy and prevention of thrombosis. 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141 (Suppl. 2).– P. 531–575.
| [PDF] | [Contents] |
Management of antithrombotic therapy in atrial fibrilltion patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association, European Association of Percutaneous Cardiovascular Interventions and European Association of Acute Cardiac Care
References
1. Ahmed I., Gertner E., Nelson W.B. et al. Continuing warfarintherapyis superior to interrupting warfarin with or with out bridgingg anticoagulation therapy in patients under going pace maker and defibrillator implantation // Heart Rhythm.– 2010.– Vol. 7.– P. 745–749.
2. Alexander J.H., Becker R.C., Bhatt D.L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial // Circulation.– 2009.– Vol. 119.– P. 2877–2885.
3. Alexander J.H., Lopes R.D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome // New Engl. J. Med.– 2011.– Vol. 365.– P. 699–708.
4. Alexander J.H., Lopes R.D., Thomas L. et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial // Eur. Heart J.– 2014.– Vol. 35.– P. 224–232.
5. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 Score // Chest.– 2013.– Vol. 144.– P. 1555–1563.
6. Armstrong M.J., Gronseth G., Anderson D.C. et al. Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology // Neurology.– 2013.– Vol. 80.– P. 2065–2069.
7. Azoulay L., Dell’Aniello S., Simon T. et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation // Thromb. Haemost.– 2013.– Vol. 109.– P. 431–439.
8. Bang C.N., Gislason G.H., Greve A.M. et al. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89 703 patients with long-term follow-up: a Nationwide Study // J. Am. Heart Assoc.– 2014.– Vol. 3.– P. e000382.
9. Bernard A., Fauchier L., Pellegrin C. et al. Anticoagulation in patients with atrial fibrillation under-going coronary stent implantation // Thromb. Haemost.– 2013.– Vol. 110.– P. 560–568.
10. Billett H.H., Scorziello B.A., Giannattasio E.R., Cohen H.W. Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit? // J. Thromb. Thrombol.– 2010.– Vol. 30.– P. 479–485.
11. Bin Abdulhak A.A., Khan A.R., Tleyjeh I.M. et al. Safety and efficacy of interrupted dabigatran for periprocedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis // Europace.– 2013.– Vol. 15.– P. 1412–1420.
12. Birnie D.H., Healey J.S., Wells G.A. et al. Pacemaker or defibrillator surgery without interruption of anticoagulation // New Engl. J. Med.– 2013.– Vol. 368.– P. 2084–2093.
13. Bonow R.O., Carabello B.A., Chatterjee K. et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons // Circulation.– 2008.– Vol. 118.– P. e523–e661.
14. BRAVO-Investigators. Effect of Bivalirudin on Aortic Valve Intervention Outcomes (BRAVO) Study. Presented at Transcatheter Therapeutics Miami Nov 8. 2011. clinical-trial results.org / Slides / BRAVO presentation And Back Up Slides 2.ppt. Last access on November 25, 2013.
15. Brugaletta S., Martin-Yuste V., Ferreira-Gonza I. et al. Adequate antiplateletre gimen in patients on chronic anti-vitamin K treatment under-going percutaneous coronary intervention // World. J. Cardiol.– 2011.– Vol. 3.– P. 367–373.
16. Buller H.R., Decousus H., Grosso M.A. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism // New Engl. J. Med.– 2013.– Vol. 369.– P. 1406–1415.
17. Caballero L., Ruiz-Nodar J.M., Marin F. et al. Oralanticoagulation improves the prognosis of octogenarian patients with atrial fibrillation under going percutaneous coronary intervention and stenting // Age Ageing.– 2013.– Vol. 42.– P. 70–75.
18. Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused up date of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association // Europace.– 2012.– Vol. 14.– P. 1385–1413.
19. Cano O., Munoz B., Tejada D. et al. Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices // Heart Rhythm.– 2012.– Vol. 9.– P. 361–367.
20. Chan W., Ajani A.E., Clark D.J. et al. Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention // Am. J. Cardiol.– 2012.– Vol. 109.– P. 471–477.
21. Chen H.C., Chen Y.L., Guo B.F. et al. Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy in-crease pocket hematoma complications in patients undergoing cardiac rhythm device implantation // Can. J. Cardiol.– 2013.– Vol. 29.– P. 1110–1117.
22. Cheng A., Nazarian S., Brinker J.A. et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial // Heart Rhythm.– 2011.– Vol. 8.– P. 536–540.
23. Chow V., Ranasinghe I., Lau J. et al. Periprocedural anticoagulation and the incidence of haematoma formation after permanent pacemaker implantation in the elderly // Heart, Lung Circ.– 2010.– Vol. 19.– P. 706–712.
24. Clemens A., Fraessdorf M., Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment // Vasc. Health Risk Manage.– 2013.– Vol. 9.– P. 599–615.
25. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet.– 2006.– Vol. 367.– P. 1903–1912.
26. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 364.– P. 806–817.
27. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation // New Engl. J. Med.– 2009.– Vol. 361.– P. 1139–1151.
28. Connolly S.J., Ezekowitz M.D.,Yusuf S. et al. New lyidentified events in the RE-LY trial // New Engl. J. Med.– 2010.– Vol. 363.– P. 1875–1876.
29. Connolly S.J., Wallentin L., Ezekowitz M.D. et al. The LongTerm Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study // Circulation.– 2013.– Vol. 128.– P. 237–243.
30. Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial // Circulation.– 2013.– Vol. 127.– P. 634–640.
31. De Caterina R., Husted S., Wallentin L. et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease // Thromb. Haemost.– 2013.– Vol. 109.– P. 569–579.
32. De Caterina R., Husted S., Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease // Thromb. Haemost.– 2013.– Vol. 110.– P. 1087–1107.
33. De Caterina R.D., Husted S., Wallentin L. et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes // J. Am. Coll. Cardiol.– 2013.– Vol. 59.– P. 1413–1425.
34. Dentali F., Riva N., Crowther M. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature // Circulation.– 2012.– Vol. 126.– P. 2381–2391.
35. Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial // Lancet.– 2013.– Vol. 381.– P. 1107–1115.
36. Di Biase L., Burkhardt J.D., Mohanty P. et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio // Circulation.– 2010.– Vol. 121.– P. 2550–2556.
37. Di Mario C., Eltchaninoff H., Moat N. et al. The 2011–12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients // Euro Intervention.– 2013.– Vol. 8.– P. 1362–1371.
38. Donze J., Rodondi N., Waeber G. et al. Scorestopredict major bleeding risk during oral anticoagulation therapy: a prospective validation study // Am. J. Med.– 2012.– Vol. 125.– P. 1095–1102.
39. Douketis J.D., Spyropoulos A.C., Spencer F.A. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141.– P. e326S–e350S.
40. Eikelboom J.W., Connolly S.J., Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves // New Engl. J. Med.– 2013.– Vol. 369.– P. 1206–1214.
41. Fauchier L., Pellegrin C., Bernard A. et al. Comparison of frequency of major advers events in patients with atrial fibrillation receiving baremetal versus drug-eluting stents in their coronary arteries // Am. J. Cardiol.– 2012.– Vol. 110.– P. 7–12.
42. Faxon D.P., Eikelboom J.W., Berger P.B. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective // Thromb. Haemost.– 2011.– Vol. 106.– P. 572–584.
43. Figulla H.R., Cremer J., Walther T. Positionspapier zur catheter gefuhrten Aorten klappen intervention // Kardiologie.– 2009.– Vol. 3.– P. 199–206.
44. Gallagher A.M., Setakis E., Plumb J.M. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients // Thromb. Haemost.– 2011.– Vol. 106.– P. 968–977.
45. Gallego P., Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation // Thromb. Haemost.– 2013.– Vol. 110.– P. 1189–1198.
46. Gao F., Zhou Y.J., Wang Z.J. et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation // Circ. J.– 2010.– Vol. 74.– P. 701–708.
47. Gerson L.B., Michaels L., Ullah N. et al. Adverse events associated with anticoagulation therapy in the periendoscopic period // Gastrointest Endosc.– 2010.– Vol. 71.– P. 1211–1217.
48. Ghanbari H., Feldman D., Schmidt M. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios // Pacing. Clin. Electrophysiol.– 2010.– Vol. 33.– P. 400–406.
49. Gilard M., Blanchard D., Helft G. et al. Antiplatelet therapy in patients with anticoagulant sunder going percutaneous coronary stenting (from STENTIng and oral antiCOagulants[STEN- TICO]) // Am. J. Cardiol.– 2009.– Vol. 104.– P. 338–342.
50. Gilard M., Eltchaninoff H., Iung B. et al. Registry of transcatheter aortic-valve implantation in high-risk patients // New Engl. J. Med.– 2012.– Vol. 366.– P. 1705–1715.
51. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation // New Engl. J. Med.– 2013.– Vol. 369.– P. 2093–2104.
52. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 365.– P. 981–992.
53. Hakalahti A., Uusimaa P., Ylitalo K., Raatikainen M.J. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment // Europace.– 2011.– Vol. 13.– P. 640–645.
54. Hamm C.W., Bassand J.P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) // Eur. Heart J.– 2011.– Vol. 32.– P. 2999–3054.
55. Hansen M.L., Sorensen R., Clausen M.T. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation // Arch. Internal. Med.– 2010.– Vol. 170.– P. 1433–1441.
56. Hawn M.T., Graham LA., Richman J.S. et al. Riskof major adverse cardiac events following non-cardiac surgery in patients with coronary stents // JAMA.– 2013.– Vol. 310.– P. 1462–1472.
57. Healey J.S., Eikelboom J., Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial // Circulation.– 2012.– Vol. 126.– P. 343–348.
58. Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace.– 2013.– Vol. 15.– P. 625–651.
59. Ho K.W., Ivanov J., Freixa X. et al. Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation // Can. J. Cardiol.– 2013.– Vol. 29.– P. 213–218.
60. Hohnloser S.H., Camm A.J. Safety and efficacy of dabigatran et exilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. // Europace.– 2013.– Vol. 15.– P. 1407–1411.
61. Hohnloser S.H., Oldgren J., Yang S. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial // Circulation.– 2012.– Vol. 125.– P. 669–676.
62. Holmes D.R. Jr., Mack M.J., Kaul S. et al. ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement // J. Am. Coll. Cardiol.– 2012.– Vol. 59.– P. 1200–1254.
63. Huber K., Airaksinen K.J., Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation under going coronary stenting: similarities and dissimilarities between North America and Europe // Thromb. Haemost.– 2011.– Vol. 106.– P. 569–571.
64. Huber K., Lip G.Y. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes // Thromb. Haemost.– 2013.– Vol. 110.– P. 11–13.
65. Huisman M.V., Lip G.Y., Diener H.C. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncer-tainties in routine practice // Thromb. Haemost.– 2012.– Vol. 107.– P. 838–847.
66. Husted S., De Caterina R., Andreotti F. et al. Esc Working Group On Thrombosis Task Force On Anticoagulants In Heart Disease OB. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel // Thromb. Haemost.– 2014.– Vol. 111.– P. 781–782.
67. Jaffer A.K., Brotman D.J., Bash L.D. et al. Variations in perioperative warfarin management: outcomes and practice patternsatnine hospitals // Am. J. Med.– 2010.– Vol. 123.– P. 141–150.
68. Kastrati A., Neumann F.J., Mehilli J. et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention // New Engl. J. Med.– 2008.– Vol. 359.– P. 688–696.
69. Kirchhof P., Ammentorp B., Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events — European Registry in Atrial Fibrillation (PREFER in AF) // Europace.– 2014.– Vol. 16.– P. 6–14.
70. Kirchhof P., Breithardt G., Aliot E. et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference // Europace.– 2013.– Vol. 15.– P. 1540–1556.
71. Kralev S., Schneider K., Lang S. et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation under going first-time coronary angiography // PloS One.– 2011.– Vol. 6.– P. e24964.
72. Krijthe B.P., Kunst A., Benjamin E.J. et al. Projections on the number of individuals with atrial fibril lationin the European Union, from 2000 to 2060 // Eur. Heart J.– 2013.– Vol. 34.– P. 2746–2751.
73. Lahtela H., Rubboli A., Schlitt A. et al. Heparin bridging vs. uninter-rupted oral anticoagulation in patients with Atrial Fibrillation under going Coronary Artery Stenting. Results from the AFCAS registry // Circ. J.– 2012.– Vol. 76.– P. 1363–1368.
74. Lakkireddy D., Reddy Y.M., Di Biase L. et al. Feasibility and safety of un interrupted rivaroxaban for periprocedural anticoagulationin patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry // J. Am. Coll. Cardiol.– 2014.– Vol. 63.– P. 982–988.
75. Lamberts M., Gislason G.H., Olesen J.B. et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention // J. Am. Coll. Cardiol.– 2013.– Vol. 62.– P. 981–989.
76. Lamberts M., Olesen J.B., Ruwald M.H. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study // Circulation.– 2012.– Vol. 126.– P. 1185–1193.
77. Lane D., Raichand S., Moore D. et al. Combined anticoagulation and antiplatelet therapy forhigh-risk patients with atrial fibrillation: a systematic review // Health Technol Assess.– 2013.– Vol. 17.– P. 1–188.
78. Larsen T.B., Rasmussen L.H., Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation: a prospective nation wide cohort study // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 2264–2273.
79. Lee C.K., Yoo S.Y., Hong M.Y., Jang J.K. Antithrombotic or antiplatelet agents in patients undergoing permanent pacemaker implantation // Korean. Circ. J.– 2012.– Vol. 42.– P. 538–542.
80. Leon M.B., Smith C.R., Mack M. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery // New Engl. J. Med.– 2010.– Vol. 363.– P. 1597–1607.
81. Li H.K., Chen F.C., Rea R.F. et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure // Pacing. Clin. Electrophysiol.– 2011.– Vol. 34.– P. 868–874.
82. Lip G.Y. Recommendation sfor thromboprophylaxis in the 2012 focused up date of the ESC guidelines on atrial fibrillation: acommentary // J. Thromb. Haemost.– 2013.– Vol. 11.– P. 615–626.
83. Lip G.Y., Bongiorni M.G., Dobreanu D. et al. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey // Europace.– 2013.– Vol. 15.– P. 1526–1532.
84. Lip G.Y., Haguenoer K., Saint-Etienne C., Fauchier L. Relationship of the SAMe-TT2R2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation // Chest. – DOI: 10.1378/ chest.13-2976.
85. Lip G.Y., Huber K., Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients pre- senting with acute coronary syndrome and/or under going percutaneous coronary intervention/stenting // Thromb. Haemost.– 2010.– Vol. 103.– P. 13–28.
86. Lip G.Y., Lane D.A. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? // Am. J. Med.– 2010.– Vol. 123.– P. 785–789.
87. Lip G.Y., Laroche C., Dan G.A. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry // Europace.– 2014.– Vol. 16.– P. 308–319.
88. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest.– 2010.– Vol. 137.– P. 263–272.
89. Lopes R.D., Li L., Granger C.B. et al. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes // Am. J. Med.– 2012.– Vol. 125.– P. 897–905.
90. Mahaffey K.W., Stevens S.R., White H.D. et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial // Eur. Heart J.– 2014.– Vol. 35.– P. 233–241.
91. Mak K.H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // B.M.J. Open.– 2012.– Vol. 2.
92. Manzano-Fernandez S., Cambronero F., Caro-Martinez C. et al. Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting // Thromb. Haemost.– 2012.– Vol. 107.– P. 51–58.
93. Marin F., Huber K., Lip G.Y. et al. Antithrombotic therapy in atrial fibrillation and stentim-plantation: treatment or threats by theuse of triple or dual antithrombotic therapy // Thromb. Haemost.– 2013.– Vol. 110.– P. 623–625.
94. McBane R.D., Wysokinski W.E., Daniels P.R. et al. Periprocedural anticoagulation management of patients with venous thromboembolism // Arterioscler. Thromb. Vasc. Biol.– 2010.– Vol. 30.– P. 442–448.
95. Mega J.L., Braunwald E., Mohanavelu S. et al. Group AA-Ts. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet.– 2009.– Vol. 374.– P. 29–38.
96. Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet.– 2009.– Vol. 374.– P. 29–38.
97. Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome // New Engl. J. Med.– 2012.– Vol. 366.– P. 9–19.
98. Mehran R., Baber U., Steg P.G. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study // Lancet.– 2013.– Vol. 382.– P. 1714–1722.
99. Mok M., Urena M., Nombela-Franco L. et al. Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation // J. Thromb. Thrombolysis.– 2013.– Vol. 35.– P. 450–455.
100. Mutuberria M., Sambola A. Bosche, Garcia del Blanco B. et al. Outcomes in patients with atrial fibrillation undergoing coronary artery stenting with a low-moderate CHA2DS2-VASc score: do they need anticoagulation? // Eur. Heart J.– 2013.– P. abstract 4093.
101. Ndrepepa G., Neumann F.J., Deliargyris E.N. et al. Bivalirudin versus heparin plus aglycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials // Circ. Cardiovasc. Interv.– 2012.– Vol. 5.– P. 705–712.
102. Oldgren J., Budaj A., Granger C.B. et al. Dabigatran vs. placebo in patients with acute coronary syn- dromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial // Eur. Heart J.– 2011.– Vol. 32.– P. 2781–2789.
103. Oldgren J., Wallentin L., Alexander J.H. et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis // Eur. Heart J.– 2013.– Vol. 34.– P. 1670–1680.
104. Pasceri V., Patti G., Pristipino C. et al. Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel // Catheter Cardiovasc. Interv.– 2010.– Vol. 75.– P. 936–942.
105. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 365.– P. 883–891.
106. Pilgrim T., Kalesan B., Zanchin T. et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents // Euro Intervention.– 2013.– Vol. 8.– P. 1061–1071.
107. Pini R., Faggioli G., Mauro R. et al. Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of perioperative bridging heparin therapy // Thromb. Res.– 2012.– Vol. 130.– P. 12–15.
108. Pisters R., Lane D.A., Nieuwlaat R. et al. Anoveluser-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest.– 2010.– Vol. 138.– P. 1093–1100.
109. Poli D., Antonucci E., Testa S., Lip G.Y. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin // Intern. Emerg. Med.– 2014.– Vol. 9.– P. 443–447.
110. Potpara T.S., Lip G.Y., Dagres N. et al. Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey // Europace.– 2014.– Vol. 16.– P. 293–298.
111. Rubboli A., Colletta M., Valencia J. et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting // J. Interv. Cardiol.– 2009.– Vol. 22.– P. 390–397.
112. Rubboli A., Kovacic J.C., Mehran R., Lip G.Y. Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options // Chest.– 2011.– Vol. 139.– P. 981–987.
113. Rubboli A., Magnavacchi P., Guastaroba P. et al. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia- Romagna Registry) // Am. J. Cardiol.– 2012.– Vol. 109.– P. 1411–1417.
114. Rubboli A., Schlitt A., Kiviniemi T. et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS Registry // Clin. Cardiol.– 2014.– Vol. 37.– P. 357–364.
115. Rubboli A., Sciahbasi A., Briguori C. et al. In-hospital management and outcome of patients on warfarin under-going coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry // J. Invasive. Cardiol.– 2013.– Vol. 25.– P. 170–176.
116. Ruff C.T., Giugliano R.P., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials // Lancet.– 2014.– Vol. 383.– P. 955–962.
117. Ruiz-Nodar J.M., Marin F., Roldan V. et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? // Circ. Cardiovasc. Intervent.– 2012.– Vol. 5.– P. 459–466.
118. Saheb K.J., Deng B.Q., Hu Q.S. et al. Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis // Chin. Med. J. (Engl).– 2013.– Vol. 126.– P. 2536–2542.
119. Sambola A., Ferreira-Gonzalez I., Angel J. et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study // Heart.– 2009.– Vol. 95.– P. 1483–1488.
120. Sambola A., Montoro J.B., Del Blanco B.G. et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial // Am. Heart J.– 2013.– Vol. 166.– P. 669–675.
121. Sarafoff N., Martischnig A., Wealer J. et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 2060–2066.
122. Schlitt A., Rubboli A., Airaksinen K.E., Lip G.Y. Antiplatelet therapy and anticoagulants // Lancet.– 2013.– Vol. 382.– P. 24–25.
123. Schlitt A., Rubboli A., Lip G.Y. et al. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation under going coronary artery stenting study // Cathet. Cardiovasc. Interv.– 2013.– Vol. 82.– P. E864–E870.
124. Smith C.R., Leon M.B., Mack M.J. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients // New Engl. J. Med.– 2011.– Vol. 364.– P. 2187–2198.
125. Smith J.G., Wieloch M., Koul S. et al. Triple antithrombotic therapy follow in ganacute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score // EuroIntervention.– 2012.– Vol. 8.– P. 672–678.
126. Smoyer-Tomic K., Siu K., Walker D.R. et al. Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation // Am. J. Cardiovasc. Drugs.– 2012.– Vol. 12.– P. 403–413.
127. Stabile E., Sorropago G., Pucciarelli A. SAT-TAVI Investigators. SAT-TAVI (Single Antiplatelet TherapyforTAVI) study: a randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation // J. Am. Coll. Cardiol.– 2011.– Vol. 58.– P. B218.
128. Steg P.G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation // Eur. Heart J.– 2012.– Vol. 33.– P. 2569–2619.
129. Steib A., Barre J., Mertes M. et al. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? // J. Thromb. Haemost.– 2010.– Vol. 8.– P. 499–503.
130. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis // Lancet.– 2007.– Vol. 370.– P. 937–948.
131. Tafur A.J., McBane R., Wysokinski W.E. et al. Predictors of major bleeding in peri-procedural anticoagulation management // J. Thromb. Haemost.– 2012.– Vol. 10.– P. 261–267.
132. Tamburino C., Ussia G.P., Maisano F. et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting // Eur. Heart J.– 2010.– Vol. 31.– P. 1382–1389.
133. Tompkins C., Cheng A., Dalal D. et al. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation // J. Am. Coll. Cardiol.– 2010.– Vol. 55.– P. 2376–2382.
134. Turpie A.G., Kreutz R., Llau J. et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor // Thromb. Haemost.– 2012.– Vol. 108.– P. 876–886.
135. UchidaY., Mori F., Ogawa H. et al. Impactofanticoagulanttherapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents // J. Cardiol.– 2010.– Vol. 55.– P. 362–369.
136. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials // Arch. Intern. Med.– 2012.– Vol. 172.– P. 397–402.
137. Ussia G.P., Scarabelli M., Mule M. et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation // Am. J. Cardiol.– 2011.– Vol. 108.– P. 1772–1776.
138. Vahanian A., Alfieri O. Guidelines on valvular heart disease in clinical practice // Euro Intervention.– 2013.– Vol. 9.– P. S11–S13.
139. Vahanian A., Alfieri O., Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012) // Eur. Heart J.– 2012.– Vol. 33.– P. 2451–2496.
140. Webb J., Rodes-Cabau J., Fremes S. et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement // Can. J. Cardiol.– 2012.– Vol. 28.– P. 520–528.
141. Wenaweser P., Rey C., Eberli F.R. et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome // Eur. Heart J.– 2005.– Vol. 26.– P. 1180–1187.
142. Whitlock R.P., Sun J.C, Fremes S.E. et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141.– P. e576S–e600S.
143. Zhao H.J., Zheng Z.T., Wang Z.H. et al. ‘Triple therapy’ rather than ‘triple threat’: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment // Chest.– 2011.– Vol. 139.– P. 260–270.
| [PDF] | [Contents] |
